GlassScriptPhysician profile
Alexander Zemtsov
NPI 1811901184
$5,868.53
in general payments reported to CMS, 2019-2025
34 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $622 · 2021: $620 · 2022: $838 · 2023: $757 · 2024: $825 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $961.32 | 2019-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $874.57 | 2019-2025 | |
| Janssen Biotech, INC. | $825.41 | 2019-2025 | Tremfya |
| Merz North America, INC. | $741.01 | 2019-2023 | Xeomin |
| Kerecis Limited | $327.51 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Mayne Pharma Commercial LLC | $273.21 | 2019-2022 | |
| Galderma Laboratories, L.P. | $208.98 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $194.93 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $168.80 | 2019-2024 | Cabtreo |
| Biofrontera INC. | $163.57 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Genzyme Corporation | $147.37 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $133.07 | 2019-2024 | Libtayo, Dupixent |
| Organogenesis INC. | $97.64 | 2023-2025 | Via Matrix, Affinity, Puraply |
| Ucb, INC. | $93.95 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $82.90 | 2022-2025 | Sotyktu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $79.86 | 2019-2023 | Adbry |
| Pfizer INC. | $70.44 | 2019-2024 | |
| Medtronic, INC. | $39.48 | 2021-2025 | Venaseal |
| Lnhc, INC | $38.54 | 2025 | Zelsuvmi |
| Dermira, INC. | $36.69 | 2019 | |
| Convatec INC. | $32.64 | 2024-2025 | |
| Lilly USA, LLC | $31.05 | 2019-2021 | |
| Tactile Systems Technology INC | $29.25 | 2022-2025 | Nimbl, Flexitouch Plus |
| Incyte Corporation | $26.38 | 2022-2023 | Opzelura |
| Journey Medical Corporation | $24.51 | 2020-2021 | |
| Hologic Sales and Service, LLC | $24.16 | 2024 | Fluent Fluid Management System, Myosure Tissue Removal Device |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.06 | 2024 | Spevigo |
| Surgenex LLC | $20.26 | 2025 | Surgraft, Ardeograft, Renograft |
| Stemline Therapeutics INC. | $19.41 | 2022 | |
| Dusa Pharmaceuticals, INC. | $19.40 | 2019 | |
| Aclaris Therapeutics, INC. | $19.01 | 2019 | |
| Celgene Corporation | $17.41 | 2024 | Sotyktu |
| Amgen INC. | $16.01 | 2021 | |
| Prugen, INC. Pharmaceuticals | $7.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Zemtsov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.